

# Special Issue

## Cutaneous Lymphoma

### Message from the Guest Editor

Primary cutaneous lymphomas (PCLs) are a heterogeneous group of non-Hodgkin lymphomas and include the more common primary cutaneous T-cell lymphomas (CTCLs) as well as primary cutaneous B-cell lymphomas (CBCLs). Despite their unifying T-cell origin, the most common CTCL subtypes (mycosis fungoides, Sézary syndrome, and CD30 lymphoproliferative disorders) exhibit a wide variety of clinical and histologic characteristics. For this Special Issue, we invite authors to submit high-quality original research and review articles that advance our understanding of PCL. Topics may include (but are not limited to) the pathophysiology of disease, molecular and biological markers for cutaneous lymphoma, novel therapies, and supportive care and quality of life.

### Guest Editor

Dr. Michi M. Shinohara

Department of Dermatology, University of Washington, Seattle, WA 98195, USA

### Deadline for manuscript submissions

31 August 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/185087](https://mdpi.com/si/185087)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)